BH3分析确定了成年早期T细胞祖细胞急性淋巴细胞白血病患者对BCL-2的依赖性。 - Suppr

BH3 profiling identifies BCL-2 dependence in adult patients with early T-cell progenitor acute lymphoblastic leukemia.

作者信息

Olesinski Elyse A, Bhatia Karanpreet S, Mahesh Aarthi N, Rosli Shazwina, Mohamed Jameelah S, Jen Wei Y, Jain Nitin, Garcia Jacqueline S, Wong Gee C, Ooi Melissa, Letai Anthony, Konopleva Marina, Bhatt Shruti

机构信息

Deparment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.

Department of Pharmacy, National University of Singapore, Singapore, Singapore.

出版信息

Blood Adv. 2023 Jun 27;7(12):2917-2923. doi: 10.1182/bloodadvances.2022007728.

DOI:10.1182/bloodadvances.2022007728

PMID:36763538

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10285538/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c93/10285538/90f5a333b7ca/BLOODA_ADV-2022-007728R2-gr1.jpg

相似文献

BH3 profiling identifies BCL-2 dependence in adult patients with early T-cell progenitor acute lymphoblastic leukemia.

Blood Adv. 2023 Jun 27;7(12):2917-2923. doi: 10.1182/bloodadvances.2022007728.

Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199.

Cancer Discov. 2014 Sep;4(9):1074-87. doi: 10.1158/2159-8290.CD-14-0353. Epub 2014 Jul 3.

Dual Targeting of Apoptotic and Signaling Pathways in T-Lineage Acute Lymphoblastic Leukemia.

Clin Cancer Res. 2023 Aug 15;29(16):3151-3161. doi: 10.1158/1078-0432.CCR-23-0415.

JAK3 mutations and mitochondrial apoptosis resistance in T-cell acute lymphoblastic leukemia.

Leukemia. 2022 Jun;36(6):1499-1507. doi: 10.1038/s41375-022-01558-5. Epub 2022 Apr 11.

ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia.

Blood. 2014 Dec 11;124(25):3738-47. doi: 10.1182/blood-2014-05-574566. Epub 2014 Oct 9.

SET-CAN fusion gene as poor prognosis predictor in adult T-cell acute lymphoblastic leukemia.

Leuk Lymphoma. 2020 Jan;61(1):217-220. doi: 10.1080/10428194.2019.1660966. Epub 2019 Sep 10.

The prognosis of CALM-AF10-positive adult T-cell acute lymphoblastic leukemias depends on the stage of maturation arrest.

Haematologica. 2013 Nov;98(11):1711-7. doi: 10.3324/haematol.2013.086082. Epub 2013 Jul 5.

An early thymic precursor phenotype predicts outcome exclusively in HOXA-overexpressing adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study.

Haematologica. 2016 Jun;101(6):732-40. doi: 10.3324/haematol.2015.141218. Epub 2016 Mar 4.

Bcl-2 maturation pattern in T-cells distinguishes thymic neoplasm/hyperplasia, T-lymphoblastic lymphoma, and reactive lymph nodes.

Cytometry B Clin Cytom. 2018 May;94(3):444-450. doi: 10.1002/cyto.b.21541. Epub 2017 Aug 1.

Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia.

Leukemia. 2014 Aug;28(8):1738-42. doi: 10.1038/leu.2014.89. Epub 2014 Feb 27.

引用本文的文献

Apoptosis-targeting BH3 mimetics: transforming treatment for patients with acute myeloid leukaemia.

Nat Rev Clin Oncol. 2025 Sep 1. doi: 10.1038/s41571-025-01068-0.

Systems biology-enabled targeting of NF-κΒ and BCL2 overcomes microenvironment-mediated BH3-mimetic resistance in DLBCL.

Cell Death Dis. 2025 Aug 16;16(1):620. doi: 10.1038/s41419-025-07942-0.

Venetoclax plus gilteritinib is effective in preclinical models of FLT3-mutant BCL11B-a lineage-ambiguous leukemia.

Blood. 2025 Aug 14. doi: 10.1182/blood.2025028985.

BCL2 inhibition in adult acute lymphoblastic leukemia: ready for primetime?

Haematologica. 2025 May 1;110(5):1053-1055. doi: 10.3324/haematol.2024.286816. Epub 2025 Feb 13.

Antileukemia efficacy of the dual BCL2/BCL-XL inhibitor AZD0466 in acute lymphoblastic leukemia preclinical models.

Blood Adv. 2025 Feb 11;9(3):473-487. doi: 10.1182/bloodadvances.2024013423.

Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts.

Blood Cancer Discov. 2024 May 1;5(3):180-201. doi: 10.1158/2643-3230.BCD-24-0001.

The relapsed acute lymphoblastic leukemia network (ReALLNet): a multidisciplinary project from the spanish society of pediatric hematology and oncology (SEHOP).

Front Pediatr. 2023 Sep 20;11:1269560. doi: 10.3389/fped.2023.1269560. eCollection 2023.

Dual Targeting of Apoptotic and Signaling Pathways in T-Lineage Acute Lymphoblastic Leukemia.

Clin Cancer Res. 2023 Aug 15;29(16):3151-3161. doi: 10.1158/1078-0432.CCR-23-0415.

本文引用的文献

venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia.

Haematologica. 2023 Jul 1;108(7):1768-1781. doi: 10.3324/haematol.2022.281692.

Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma.

Cancer Discov. 2021 Jun;11(6):1440-1453. doi: 10.1158/2159-8290.CD-20-1465. Epub 2021 Feb 16.

Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia.

Cancer Cell. 2020 Dec 14;38(6):872-890.e6. doi: 10.1016/j.ccell.2020.10.010. Epub 2020 Nov 19.

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.

N Engl J Med. 2020 Aug 13;383(7):617-629. doi: 10.1056/NEJMoa2012971.

Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia.

Clin Lymphoma Myeloma Leuk. 2020 Apr;20(4):212-218. doi: 10.1016/j.clml.2019.09.608. Epub 2019 Sep 30.

Prediction of venetoclax activity in precursor B-ALL by functional assessment of apoptosis signaling.

Cell Death Dis. 2019 Jul 29;10(8):571. doi: 10.1038/s41419-019-1801-0.

Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.

N Engl J Med. 2018 Mar 22;378(12):1107-1120. doi: 10.1056/NEJMoa1713976.

Early Response-Based Therapy Stratification Improves Survival in Adult Early Thymic Precursor Acute Lymphoblastic Leukemia: A Group for Research on Adult Acute Lymphoblastic Leukemia Study.

J Clin Oncol. 2017 Aug 10;35(23):2683-2691. doi: 10.1200/JCO.2016.71.8585. Epub 2017 Jun 12.

Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia.

Blood. 2017 Mar 16;129(11):e26-e37. doi: 10.1182/blood-2016-09-738070. Epub 2017 Jan 25.

Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia.

Cancer Discov. 2016 Oct;6(10):1106-1117. doi: 10.1158/2159-8290.CD-16-0313. Epub 2016 Aug 12.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

BH3 profiling identifies BCL-2 dependence in adult patients with early T-cell progenitor acute lymphoblastic leukemia.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

BH3 profiling identifies BCL-2 dependence in adult patients with early T-cell progenitor acute lymphoblastic leukemia.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献